Nucleus accumbens
Nucleus accumbens septi
subcortical
The ventral expansion of the striatum, sitting between the head of the caudate dorsally and the olfactory tubercle ventrally. Conventionally subdivided into a core (continuous with surrounding striatum) and a shell (more limbic, with closer ties to the extended amygdala). The accumbens is the principal target of the mesolimbic dopamine projection from the ventral tegmental area.
The nucleus accumbens is the cortical-subcortical hub of the reward and motivation system. It receives convergent input from prefrontal cortex (carrying contextual information about expected outcomes), amygdala (carrying affective valence), and hippocampus (carrying contextual memory), and integrates these with dopaminergic input from VTA that signals reward prediction error.
Phasic dopamine release in the accumbens reinforces actions that lead to better-than-expected outcomes and underwrites the formation of stimulus-reward associations. The accumbens is therefore central to drug reinforcement, addiction, and motivation broadly. Most addictive drugs converge on the accumbens by either increasing dopamine release there directly (cocaine, amphetamine) or disinhibiting VTA dopamine neurons (nicotine, opioids, alcohol).
default-mode
Mogenson, Jones, and Yim’s 1980 paper “From motivation to action” framed the nucleus accumbens as the interface between the limbic system (which signals affective and motivational state) and the motor system (which executes goal-directed behaviour). The framing has held up across four subsequent decades of work and remains the canonical model for how organisms translate “wanting” into action.
The mesolimbic dopamine pathway from the ventral tegmental area to the accumbens has been called “the final common pathway of addiction” because so many disparate addictive substances converge on increasing accumbens dopamine. Recovery from addiction involves both extinction of learned cue-reward associations (mediated by accumbens-prefrontal circuits) and reduction in cue-evoked dopamine release.
Deep brain stimulation of the accumbens has been trialled for treatment-resistant obsessive-compulsive disorder, severe depression, and alcohol-use disorder. Acute mood-elevating effects of stimulation are reproducible and sometimes dramatic, including reports of laughter and euphoria during intraoperative testing. Long-term clinical efficacy in randomised trials has been more modest than initial open-label case series suggested.